Agomelatine: to be avoided, with or without a "patient booklet".
In early 2015, the European health authorities chose to keep agomelatine on the market despite its serious adverse effects (especially hepatic disorders), simply because patients would be provided with a treatment booklet. Yet this flimsy measure in no way improves patient care.